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Abstract
Pharmacological modulation of ATP-sensitive potassium channels has become a promising new therapeutic approach for
the treatment of neurodegenerative diseases due to their role in mitochondrial and cellular protection. For instance,
diazoxide, a well-known ATP-sensitive potassium channel activator with high affinity for mitochondrial component of the
channel has been proved to be effective in animal models for different diseases such as Alzheimer’s disease, stroke or
multiple sclerosis. Here, we analyzed the ability of diazoxide for protecting neurons front different neurotoxic insults in vitro
and ex vivo. Results showed that diazoxide effectively protects NSC-34 motoneurons from glutamatergic, oxidative and
inflammatory damage. Moreover, diazoxide decreased neuronal death in organotypic hippocampal slice cultures after
exicitotoxicity and preserved myelin sheath in organotypic cerebellar cultures exposed to pro-inflammatory demyelinating
damage. In addition, we demonstrated that one of the mechanisms of actions implied in the neuroprotective role of
diazoxide is mediated by the activation of Nrf2 expression and nuclear translocation. Nrf2 expression was increased in NSC-
34 neurons in vitro as well as in the spinal cord of experimental autoimmune encephalomyelitis animals orally administered
with diazoxide. Thus, diazoxide is a neuroprotective agent against oxidative stress-induced damage and cellular dysfunction
that can be beneficial for diseases such as multiple sclerosis.
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Introduction
ATP-sensitive potassium (KATP) channels are ubiquitous ion
channels coupling cell metabolism to electrical activity by
regulating the potassium flow across the cell membrane. These
channels act as energy sensors of ATP production and are believed
to regulate various physiological functions, such as muscle
contraction and insulin secretion, by coupling ATP/ADP balance
to membrane potential [1,2]. In the central nervous system (CNS),
KATP channels are described to be important in glucose sensing in
different areas including the midbrain (substantia nigra), pons
(locus coeruleus) and medulla (nucleus of the solitary tract) [3,4].
KATP channels also play a role in neurosecretion at nerve
terminals. [5,6].
KATP channels are also present at the mitochondrial inner
membrane (mito-KATP). Mito-KATP channels participate in the
regulation of mitochondrial volume, ionic homeostasis, pH
gradient and membrane potential [7]. Furthermore, their activity
is related to electronic transport, metabolic energy, reactive
oxygen species (ROS) production and mitochondrial welfare and
can be an interesting target for neuroprotective therapies [8,9].
Mito-KATP channels are identified in liver mitochondria [10],
heart [11], kidney [12], skeletal muscle [13] and brain [14], where
it has been estimated to contain six to seven times more mito-KATP
concentration than liver or heart. Activation of these channels
allows potassium ions to flow into mitochondria which results in
depolarization and may initiate neuronal preconditioning [15].
Diazoxide (7-chloro-3-methyl-4H-1,2,4-benzothiadiazine 1,1-
dioxide), a well-known small molecule that opens KATP channels
with high affinity for mito-KATP channels, has been reported to
cause cardio and neuroprotection. This effect has been mainly
attributed to its ability to decrease calcium overload from the
extracellular space [16], but more important, due to its activity in
regulating mitochondrial homeostasis [17]. Diazoxide demonstrat-
ed neuroprotective effects in cerebral ischemia-reperfusion injury
diminishing levels of reactive oxygen species, decreasing DNA
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oxidative damage, and inhibiting caspase-dependent and -inde-
pendent apoptotic pathways while preserving mitochondrial
structure [18–20]. The opening of KATP channels by diazoxide
can modulate the nigro-striatal pathway reducing akinesia in a
dose-dependent manner in a reserpine-treated rat model of
Parkinson disease (PD) [21]. In addition, neuroprotective effects
on dopaminergic neurons by regulating glial reactivity though
mito-KATP activation has been also described [22,23]. Other
authors demonstrated that diazoxide is able to protect neurons
against b-amyloid toxicity, reduce protein aggregates and tau
hyperphosphorilation and to improve cognitive function and
learning behavior [24–26]. Thus, KATP channels and its pharma-
cological modulation are recognized as potential targets and
neuroprotective treatments of several neurodegenerative diseases
such as ischemia, PD or Alzheimer’s diseases (AD) [26–29].
We previously reported that oral administration with diazoxide
ameliorated clinical signs on myelin oligodendrocyte glycoprotein
peptide (MOG35-55)-induced experimental autoimmune enceph-
alomyelitis (EAE), a murine model of multiple sclerosis (MS). At
histological level diazoxide elicited a significant reduction in
myelin and axonal loss accompanied by a decrease in glial
activation and neuronal damage without affecting the number of
infiltrating lymphocytes positive for CD3 and CD20 in the spinal
cord [30]. Thus, these results demonstrated a novel action of
diazoxide for preventin brain damage in neuroinflammation. MS
pharmacotherapy is dominated by immunomodulatory drugs,
which were developed to reduce the incidence and intensity of new
inflammatory lesions by limiting the activity of immune cells
without acting directly on preventing CNS damage. However, in
the last years, the therapeutic landscape for MS is rapidly
changing and the development of drugs with primarily CNS
neuroprotective effects is currently a pharmaceutical reality.
Among other neuroprotective strategies, the activation of cellular
self-defense against oxidative stress, particularly the transcription
factor nuclear factor (erythroid-derived 2)-related factor 2 (Nrf2)-
mediated pathway has been postulated as a novel therapeutic
approach for the treatment of neurodegenerative disease [31,32].
For instance, the activation of Nrf2 nuclear translocation has been
described as the main mechanism of action involved in the
beneficial effect of fumaric esters for the treatment of MS [33].
Nrf2 mediates the activation of detoxifying phase II enzymes via
mitochondrial oxidative stress signaling [34,35] where mito-KATP
channels function play a crucial role [36]. This pathway may thus
play a critical role for cellular protection in an environment of
oxidative stress and may represent an interesting therapeutic target
in neurodegenerative diseases.
Consequently, the aims of the present study were: (a) to study
the protective effects of diazoxide against excitotoxicity, oxidative,
pro-inflammatory and demyelinating insults, and (b) to analyze the
effects of diazoxide in activating the anti-oxidative self-defense in
neurons, proposing a novel neuroprotective mechanism of action
based on Nrf2 activation.
Materials and Methods
Ethics Statement
Animal were handled according to European legislation (86/
609/EU) and procedures were approved by the Ethics and
Scientific Committees of the University of Barcelona and
registered at the ‘‘Departament d’Agricultura, Ramaderia i Pesca,
Generalitat de Catalunya, Spain’’.
Reagents
Diazoxide was purchased from Sigma-Aldrich (St. Louis, MO,
USA). Stock solutions (50 mM) of diazoxide were prepared in
dimethyl sulfoxide (DMSO, Sigma-Aldrich). Solutions for cell
treatment were prepared by diluting stock solutions in culture
media immediately before being added to the cells (DMSO
concentration: 0.5%). Solutions for animal treatment were
prepared by diluting stock solution in water every day of the
treatment (DMSO concentration: 0.3%).
Mice
Female C57BL/6J mice, 8 to 10 weeks of age, were purchased
from Charles River (Sulzfeld, Germany) and maintained on a
12:12 h light:dark cycle, with standard chow and water freely
available.
EAE induction and treatment
EAE was induced by immunization with . 95% pure synthetic
MOG35-55 peptide (rat MOG35-55, MEVGWYRSPFSRVVH-
LYRNGK; EspiKem Srl, Florence, Italy). Mice were injected
subcutaneously at one side of the flank with 100 mL solution
containing 150 mg of rat MOG in complete Freund’s adjuvant
(Sigma-Aldrich) and 5 mg/mL Mycobacterium tuberculosis
H37Ra (Difco Laboratories, Detroit, MI, USA). Mice also
received intraperitoneal injections of 150 ng pertussis toxin
(Sigma-Aldrich) in 100 mL phosphate-buffered saline (PBS)
immediately after MOG injection and 48 h later.
To study Nrf2 activation in diazoxide treated EAE mice, two
different administration protocols were performed: in the first one,
treatment began on the first day of EAE induction (preventive)
whereas the second one started in the chronics phase, when the
EAE clinical score was $ 1 (appearance of clinical signs,
therapeutic). The MOG-immunized mice were administered
either 0.8 mg/kg diazoxide (treated group) or diluent (0.3%
DMSO in water, vehicle group) for 30 or 15 days by oral gavage,
respectively.
NSC-34 cell culture experiments
Motoneuronal NSC-34 cell line (Cellutions Biosystems Inc,
Cedarlane, Ontario, Canada) was a gift from Dr. Villoslada
(IDIBAPS, Barcelona, Spain). Cells were cultured at 37uC and 5%
CO2 in Dulbecco’s modified Eagle’s medium (DMEM) supple-
mented with 10% fetal bovine serum (FBS), 1% penicillin/
streptomycin and 0.04 mM L-glutamine (all from Invitrogen,
Eugene, OR, USA). To differentiate NSC-34 cells to a motoneu-
ronal and glutamate-responsive phenotype, DMEM was replaced
by DMEM/Ham’s F12 (Invitrogen) supplemented with 1% FBS,
1% penicillin/streptomycin and 1% modified Eagle’s medium
nonessential amino acids (Sigma-Aldrich) [37]. NSC-34 cells were
seeded at low density (36104 cells/ml) in 24-well plates and were
used 72 h after seeding for the toxicity assays. For the treatments,
control wells contained the same final concentration of vehicle as
the compound-containing wells (0.5% DMSO).
Glutamate toxicity assay. NSC-34 cells were allowed to
differentiate for 8 weeks under reduced serum conditions and then
seeded in 24-well plates at a density of 36104 cells/ml for the
following experiment. Glutamate (Sigma-Aldrich) was dissolved in
culture medium and added to cultures at concentration of 10 mM
for 24 h. Cell treatment with 100 mM diazoxide started 2 h before
glutamate exposure. Cell viability was measured by the 3-[4,5-
dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) as-
say.
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Hydrogen peroxide exposures. To induce oxidative stress,
hydrogen peroxide (H2O2) was added to final concentration of
0.2 mM (Stock 30%, Sigma-Aldrich). NSC-34 cells were exposed
to H2O2 for 30 min at 37uC. Then the medium was removed and
replaced with fresh medium for 24 h. Cells were treated with
100 mM diazoxide 2 h before H2O2 injury and during 24 h after.
Cell viability was measured by the MTT assay.
BV2 conditioned medium. To test inflammatory damage,
conditioned medium (CM) from unstimulated and Lipopolysa-
charide (LPS, Sigma-Aldrich) plus gamma Interferon (IFN-c,
Sigma-Aldrich) activated BV2 microglia was used to damage
neuron cells. BV2 cells were seeded and activated as previously
described [30]. Cell medium was collected 24 h after activation
and then used to replace NSC-34 medium. NSC-34 viability was
measured 24 h after BV2 CM exposure by MTT assay. Diazoxide
(100 mM) was tested in two ways: in the first one, it was added to
BV2 cells prior to activation and in the second one, drug was
added to NSC-34 cells before CM addition.
2,2’-azobis-2-methyl-propanimidamide, dihydrochloride
(AAPH) exposure. AAPH, a free radical generating azo
compound, was used to induce oxidative stress. NSC-34 cells
were pretreated for 2 h with different concentrations of diazoxide
(100, 10, 1 and 0.1 mM). Then, the medium was removed and
replaced with fresh medium containing AAPH 9 mM (Sigma-
Aldrich). Cells were then maintained with the treatment for 24 h at
37uC and cell viability was measured by MTT assay.
3-(4,5-Dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium
bromide reduction method (MTT)
MTT reduction assay was used as an indicator of cell viability.
MTT (Sigma-Aldrich) was added to a well at a final concentration
of 0.5 mg/mL. After MTT incubation at 37uC, DMSO was
added and cells were gently resuspended. Absorbances at 560 and
620 nm were recorded with a microplate reader (BioTek ELX800,
BioTek Instruments Inc., Vermont, USA). Mean values of at least
three independent wells from three experiments were calculated,
and cell survival was expressed as percentage MTT-positive cells
compared with untreated control cells.
Immunofluorescence for Nrf2 in spinal cord
Histological procedures for coronal spinal cord EAE mice
sections followed the same methodology previously described [30].
The following antibodies were used: anti-NeuN (1:100, Millipore,
Bedford, MA, USA) and anti-Nrf2 (1:75, Santa Cruz Biotechnol-
ogy). The secondary antibodies used were AlexaH488 and 596
(from 1:2000 to 1:1000, Molecular Probes, Invitrogen, Eugene,
OR, USA). Double immunofluorescent staining was performed
after citrate Heat-Induced Epitope Retrieval (HIER) of the
samples as previously described [30].
Images were captured using both wide field microsope Leica
AF7000 and SP1 confocal microscope (Leica Microsystems
GmbH, Wetzlar, Germany), located at the Parc Cientı́fic de
Barcelona, Barcelona, Spain.
Isolation of nuclear and total proteins for Nrf2 Western
Blot
Nrf2 level was determined in nuclear protein extracts from
NSC-34 cell cultures 24 h after treatments, using 3 wells from 6-
well plates for each experimental condition. Nuclear protein
extraction from cell cultures were performed as previously
described [38]. Protein concentration was determined by the
Lowry assay (Total Protein kit micro-Lowry, Sigma-Aldrich). For
total protein extraction for in vivo western blot spinal cord samples
were first sonicated at 4uC in RIPA buffer (Sigma-Aldrich), and
protease inhibitor cocktail Complete (Roche Diagnostics, Basel,
Switzerland). After 30 min of incubation on ice, samples were
centrifuged at 5000 rpm for 5 min at 4uC and the supernatants
were collected. Protein concentration was determined by the
Lowry assay as above.
Western blot
Western blot analyses for total and nuclear extracts (40 mg of
denatured protein) were performed as described [30]. Briefly,
polyvinylidene difluoride membrane (Millipore) with protein
extracts were incubated with primary antibodies: polyclonal rabbit
anti-Nrf2 (1:300, Santa Cruz Biotechnology), polyclonal goat anti-
lamin B (1:7500, Santa Cruz Biotechnology) and monoclonal
mouse anti-actin (1:100000, Sigma-Aldrich) and secondary anti-
bodies donkey anti-rabbit (1:5000, Amersham, Buckinghamshire,
UK), donkey anti-goat (1:2000, Santa Cruz Biotechnology), and
donkey anti-mouse (1:5000, Santa Cruz Biotechnology) respec-
tively. Western blotting detection was performed with ECL Plus
(Amersham). The membranes were then exposed to the camera
and the pixel intensities of the immunoreactive bands were
quantified using the percentage adjusted volume feature of
Quantity One 5.6.4 software (Bio-Rad Laboratories, Hercules,
CA, USA). Data were expressed as the ratio of the band intensity
of the protein of interest to the loading control protein band (lamin
B for nuclear extracts and b-actin for total extracts).
Organotypic hippocampal slice cultures (OHSCs)
Organotypic hippocampal slice cultures were prepared as
previously described with minor modifications [39]. In brief, slice
cultures were prepared from 2 to 3 days old C57BL/6 J mouse
pups under sterile conditions. After decapitation, the brains were
removed and the hippocampi from both hemispheres were acutely
isolated on ice cold serum-free Hank’s Balanced Salt Solution
(HBSS, PAA, Piscataway, USA), supplemented with 0.5% glucose
(Sigma-Aldrich) and 15 mM HEPES (PAA). Isolated hippocampi
were cut into 350-375 mM thick slices using a tissue chopper
(McIlwain, MickleLab, United Kingdom) and were transferred to
0.4 mM culture plate inserts (Millipore). Four to six slices per
insert, were placed in six-well plates containing 1.2 ml of culture
medium per well. Culture medium (pH 7.2) consisted of 0.56
minimum essential medium (MEM, Invitrogen) containing 25%
heat-inactivated horse serum (PAA), 25% BME basal medium
without glutamate (Invitrogen), 2 mM glutamax and 0.65%
glucose (Sigma-Aldrich). The slice cultures were kept at 35uC in
a humidified atmosphere (5% CO2). Culture medium was
refreshed the first day after preparation and every consecutive 2
days.
Depletion of microglia from slice cultures. Depletion of
microglia from hippocampal slices was carried out as previously
reported [39,40]. In brief, slices were placed on culture plate
inserts and incubated with approximately 0.5 mg/ml Lip-CL
solution (1:10 liposome dilution in standard culture medium)
(ClodronateLiposomes.org, Amsterdam, The Netherlands) for 24
h at 35uC. Subsequently, slice cultures were carefully rinsed in
PBS (35uC) to wash away residual liposomes and placed on fresh
culture medium. After depletion the medium was refreshed every
2 days.
Excitotoxic lesion and treatment in hippocampal
slices. After 7 days in vitro (DIV), slices were placed in medium
containing 10 mM N-methyl-D-aspartic acid (NMDA, Sigma) for
4 h. For diazoxide treatment, different concentrations of the drug
(200, 100, 10, 1 mM) were placed 30 min before NMDA lesion.
Subsequently, the medium was replaced with standard culture
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medium containing different concentrations of diazoxide for 24 h
after the NMDA damage. To quantify neuronal cell death in
response NMDA-induced excitotoxicity, slice cultures were
incubated with 5 mg/ml propidium iodide (PI, Sigma-Aldrich),
during and after NMDA insult. After 24 h NMDA treatment,
slices were rinse twice in PBS and fixed with 4% PFA overnight
and stained with NeuN to localize the neuron population
colocalizating with PI staining. Confocal images of neuronal cell
layers were acquired at 10X magnification. For cell death
quantification, 6 slices per condition were used in each experi-
ment. Cell death in the CA1 layer was quantified by total PI
uptake (fluorescent intensity) using ImageJ software and was
expressed as percentage of PI uptake compared with untreated
control slices.
Organotypic cerebellar slice cultures (OCSCs)
The cerebellar slices cultures were prepared as previously
reported [41,42]. Briefly, parasagittal slices of postnatal at days 7-9
(P7-P9) mouse cerebellum were cut at 350 mm using a tissue
chopper (McIlwain) and were transferred to 0.4 mM culture plate
inserts (Millipore). Cerebellar slices were cultured in 50% basal
medium with Earle’s salts, 25% Hank’s buffered salt solution, 25%
horse serum, 5 mg/ml glucose (all from Invitrogen) at 37uC and
5% CO2. Three slices were placed in each culture plate insert.
Culture medium was refreshed the first day after preparation and
every consecutive 2 days. For LPS induced demyelination,
medium was removed after 7 DIV and fresh medium with
15 mg/mL LPS was added for 24 h. For diazoxide treatment, 10-
1 mM diazoxide was added 30 min before LPS treatment and
during 24 h. After that, slices were rinse in PBS and fixed with 4%
PFA overnight for immunostaining. OCSCs were stained for
heavy neurofilament (NFH) and myelin (Myelin Basic Protein,
MBP) to quantify demyelination. Confocal microscopy was used to
obtain stacks of images at 2 mm intervals at 63X magnification. A
total of 10 confocal z-stacks were done for each condition per
experiment. An imageJ macro designed to calculate NFH intensity
without MBP colocalization was used to quantify demyelination.
Axon demyelination was quantified as percentage of NFH without
colocalization with MBP from total NFH staining.
Immunostaining for organotypic cultures
After fixation, organotypic slices were cut from the insert and
placed in a 24 well plate. Slices were blocked for 1 h with
PBS+10% NGS+0.3% Triton X-100 (Sigma-Aldrich) at 4uC.
Primary and secondary antibody incubations were done overnight
at 4uC in PBS+1% NGS+0.3% Triton X-100. After incubations,
slices were washed three times in PBS. Finally, slices were
mounted on slides and cover slipped using ProLong Gold
(Invitrogen). The following primary antibodies were used: NeuN
(mouse monoclonal, 1:800, Millipore); Neurofilament H (NFH,
mouse monoclonal, 1:800, Abcam) and myelin basic protein
(MBP, rabbit polyclonal, 1:400, Abcam). Secondary antibodies
were Alexa Fluor 488 or Alexa Fluor 568 conjugated anti-mouse
or anti-rabbit from Molecular Probes. Imaging was carried out
using Zeiss LSM or Leica SP5 Spectral confocal microscope.
TNF-a and IL-6 determination
The amount of TNF-a and IL-6 released into the culture media
from OCSCs was determined using an Enzyme-linked immuno-
sorbent assay (ELISA) kit specific for mouse TNF-a (Mouse TNF-
a Ready-SET-Go!H) and for mouse IL-6 (Mouse IL-6 Ready-
SET-Go!H) (both from eBioscience, San Diego, CA, USA)
according to the manufacturer’s instructions.
Statistical Analysis
Data were expressed as the mean 6 SEM unless specified.
Statistical analysis of cell treatments was carried out using one-way
ANOVA, using repeated measures ANOVA when appropriate,
followed by Newman-Keuls post test when three or more
experimental groups were compared and Student’s t-test when
only two groups were compared. Values of p,0.05 were
considered statistically significant.
Results
Diazoxide improves NSC-34 motoneuron survival after
excitotoxic, oxidative and inflammatory damage
To examine the protective effect of diazoxide, we tested its
effects in NSC-34 motoneurons subject to different neurotoxic
insults. When diazoxide effects were tested during glutamatergic
insult, results showed that the compound protected motoneuron
cells against glutamate toxicity (Figure 1A), producing a significant
increase of cell viability (1661% vs untreated damaged cells,
Figure 1B). Second, H2O2 was used to produce exogenous ROS
damage (viability loss 6868%, Figure 1C-D). Diazoxide produced
a significant increase of NSC-34 viability after H2O2 challenge in
comparison to untreated cells when the treatment was maintained
during 24 h (31613%, Figure 1C) but also when the drug was
removed just after the H2O2 damage (1765%, Figure 1D).
Finally, when diazoxide was tested during inflammatory damage,
treatment produced a significant increase of NSC-34 viability in
both paradigms: by protecting neurons against BV2 conditioned
medium (CM) and by decreasing BV2 neurotoxicity (1063% and
1265% increase vs untreated condition, Figure 1E). These results
demonstrate that diazoxide could protect NSC-34 neurons against
the main sources of neurodegenerative damage.
Neuroprotective effects of diazoxide in mouse OHSCs are
maintained after microglia depletion
To examine the effects of diazoxide in a model of neuronal
degeneration induced by NMDA excitotoxicity, OHSCs were
used. After 7 DIV, the neuronal layers CA1, CA3 and dentate
gyrus (DG) were well preserved and neuronal cell death was
minimal (,1%, Figure 2A). Treatment with 10 mM NMDA for 4
h induced a region-specific neuronal cell death in CA1 layer with
minor affectation of CA3 layer and DG (Figure 2B). When
OHSCs were pretreated for 30 min with different concentrations
of diazoxide, hippocampal damage, measured as PI uptake, was
reduced (Figure 2C, D). A significant prevention in cell death was
observed at 100 mM diazoxide (6566% in PI uptake compared to
control) but also at the lowest dose tested, 1 mM (6767% in PI
uptake compared to control) (Figure 2E).
In order to elucidate whether the neuroprotective effect of
diazoxide in OHSCs was mediated by microglia, microglial cells
were depleted from mouse slice cultures using liposomes-encap-
sulated clodronate (Lip-CL). Lip-CL has been shown to success-
fully deplete microglia from mouse organotypic slice cultures,
without affecting other cell-types [39,43] or hippocampal archi-
tecture (Figure 2F). As previously described [40], neuronal cell
death in microglia-depleted slice culture was enhanced in response
to 10 mM NMDA compared to normal OHSC (Figure 2G). When
slices were pretreated with different doses of diazoxide (200-1 mM),
the protective effect at the high doses was abolished (Figure 2H)
but protection remained at the lowest dose 1 mM (62610% PI
uptake compared to control, Figure 2I, J). These results indicate
that the protective effects of diazoxide observed could be partially
mediated by microglia.
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Diazoxide protects against demyelination in LPS-
neuroinflammation model in organotypic cerebellar
cultures
To explore whether diazoxide prevents demyelination and
axonal damage, a LPS-mediated demyelination model in cerebel-
lar organotypic cultures was used. As previously reported,
treatment with 15 mg/mL LPS for 24 h promotes microglial
activation and consequent demyelination and axonal damage [41].
In our cultures, slices treated with 15 mg/mL LPS for 24 h showed
a decrease in MBP intensity and an increase of myelin debris
(Figure 3A). When slices were treated with 10 mM diazoxide
during injury, a better preservation of myelin structure was
observed (Figure 3A). Lower diazoxide concentrations also showed
positive effects on myelin preservation (data not shown). At higher
magnification, demyelination was observed in LPS treated slices
(Figure 3B). Demyelinated axon quantification, measured as heavy
neurofilament (NFH) intensity without colocalization with myelin
(MBP signal), showed a 15% increase of demyelinated axons in
LPS treated slice compared to control (4463% vs 2962%,
respectively). Treatment with diazoxide significantly prevents
myelin loss induced by LPS (4463% from LPS treated slices vs
3362% from diazoxide LPS treated slices) (Figure 3C). In order to
prove whether pro-inflammatory signals derived from LPS
treatment were modified by diazoxide, IL-6 and TNF-a content
in the medium was analyzed. Results showed that these
inflammatory mediators were decreased in treated slices (Figure
3D). This decrease was statistical significant for TNF-a
(480667 pg/mL from LPS treated slices vs 374682 pg/mL and
350660 pg/mL from 10 mM and 1 mM diazoxide LPS treated
slices, respectively). Taken together, these results show the
neuroprotective effects of diazoxide in pro-inflammatory demye-
linating insults.
Diazoxide promotes nuclear Nrf2 translocation and
decreases oxidative cell damage at low doses in NSC-34
motoneuron
To elucidate whether pharmacological activation of anti-
oxidative pathways was involved in the direct neuroprotection
exerted by diazoxide in NSC-34 neurons, we performed an
analysis of Nrf2 expression 24 h after diazoxide treatment.
Immunoblotting analysis demonstrated an important increase of
Nrf2 signal in nuclear fraction of NSC-34 cells treated with
diazoxide. Interestingly, the increase was higher at low doses of the
compound (Figure 4A). To explore whether the increase of Nrf2
nuclear translocation on NSC-34 at low doses was correlated with
an increase of cell viability in presence of endogenous oxidative
stress, cell survival was analyzed after AAPH exposure. In
concordance with the previous results, diazoxide treatment
significantly ameliorated cell survival at low doses (1 mM and
0.1 mM) (Figure 4B, 8.162.7% and 10.761.6%, respectively)
Diazoxide treatment promotes Nrf2 translocation and
causes neuroprotection in EAE mice spinal cord
Nrf2 levels were also measured by western blot using total spinal
cord homogenates from EAE animals treated with oral diazoxide
(preventively and therapeutically) and control mice. Results
showed a significant increase of Nrf2 immunostaining in diazoxide
treated animals when compared to vehicle mice (Figure 5A, B).
Figure 1. Diazoxide prevents neuronal damage after different neurotoxic insults. Representative images of differentiated NSC-34
motoneuron cells line after glutamate damage and diazoxide treatment (A). Diazoxide inhibited glutamate mediated cell death by 24 h in
differentiated NSC-34 motoneuron cell line (B). Diazoxide inhibited H2O2 mediated cell death by 24 h (C) and also when used as pretreatment during
2 h (survival analysis performed 24 h after toxic insult) (D). Diazoxide inhibited inflammatory BV2 microglial mediated cell death by 24 h in NSC-34
motoneuron. Conditioned Medium (CM): Neurons damaged with activated BV2 medium. CM (Dxz to NSC-34): Neurons treated with diazoxide and
damaged with activated BV2 medium afterwards. CM (Dzx to BV2): Neurons damaged with diazoxide treated BV2 activated medium (E). Diazoxide
treatment 100 mM. Results expressed as mean 6 SEM. n$4 experiments. *: p , 0.05. Scale bar = 30 mm
doi:10.1371/journal.pone.0075189.g001
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Next, histological observation of diazoxide treated and control
spinal cords from EAE animals were performed. Control EAE
mice showed signs of neurodegeneration, characterized by nuclear
pigmentation, loss of tissue integrity and decrease of NeuN
immunoreactivity, a classic marker for functional mature neurons
(Figure 5C). Diazoxide treated animals showed higher NeuN stain
and higher preservation of the grey matter than vehicle control
EAE animals (Figure 5C, F). Double immunofluorescence analysis
of diazoxide treated animals showed a nuclear translocation for
Nrf2 in NeuN positive motoneuron, demonstrating an activation
of Nrf2 anti-oxidative pathway (Figure 5D, E vs Figure 5G, H,
white arrows). Thus, activation of endogenous antioxidative self-
defense could be involved in beneficial effect of diazoxide in EAE
mice.
Discussion
The use of selective agonists of KATP channel has been found to
protect cell death in many cell types against excitotoxicity,
oxidative stress or inflammatory insult [44–46] and to produce
beneficial outcomes in different animal models of neurodegener-
ative pathologies [26,30,47]. We have previously demonstrated
that diazoxide ameliorates disease progression in a murine model
of MS, decreasing axonal loss and preventing neuron integrity in
the spinal cord of EAE mice [30]. We showed that diazoxide could
mediate an inhibition of microglial pro-inflammatory behavior
that could be beneficial for EAE clinical course. Although these
studies suggest that diazoxide has a neuroprotective effect in EAE,
it is not clearly understood whether it is a direct effect to neurons
Figure 2. Diazoxide effects in NMDA-induced neurodegeneration in hippocampal slice culture. At 7 DIV, treatment with 10 mM NMDA
for 4 h induced a region-specific increase neuronal cell death of the CA1 layer compared to undamaged slices, as determined as PI uptake (PI, red) in
colocalization with the neuronal nuclear marker NeuN (green) (A, B). Treatment 30 min before NMDA lesion with diazoxide prevented cell death,
significantly at 100 mM but also at lowest dose 1 mM (C, D). Upon quantification, results showed a significant decrease at 100 mM (6565% in PI uptake
compared to control) and 1 mM (6767% in PI uptake compared to control (E). When microglia was removed from the slices, cell protection remained
at the lowest dose 1 mM (62610% in PI uptake compared to control) (F-J). Data are a summary of four to seven individual experiments with 6 slices
per conditions analyzed in each experiment. Results are shown as mean 6 SEM. * p,0.05, ** p,0.01. Scale bar 300 mm
doi:10.1371/journal.pone.0075189.g002
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Figure 3. Diazoxide prevents LPS-induced demyelination in organotypic cerebellar culture. Cerebellar slices were treated with 15mg/ml
LPS to induce demyelination as shown with heavy neurofilament (NFH, red) and myelin basic protein (MBP, green) immunostaining. Representative
images from untreated, LPS and LPS+10 mM diazoxide treated cerebellar slices demonstrated that treatment preserved MBP staining and prevented
myelin debris accumulation (A). Higher magnifications of axons from untreated, LPS and LPS+10 mM diazoxide treated cerebellar slices are shown.
Small panels show total NFH intensity (Total axons) and NFH staining without colocalization with MBP staining (Demyelinated axons) (B). Axon
demyelination was quantified as percentage of NFH without colocalization with MBP from total NFH staining. Upon quantification of axon
demyelination, results showed that diazoxide reduced axonal myelin loss when compared to LPS treated slices (3362% vs 4463%, respectively) (C).
10 and 1 mM diazoxide also reduced TNF-a and IL-6 release derived from LPS stimulation in cerebellar cultures. This decrease was statistical significant
for TNF-a (480667 pg/mL from LPS treated slices vs 374682 pg/mL and 350660 pg/mL from 10 mM and 1 mM diazoxide LPS treated slices,
respectively) (D). Results are shown as mean 6 SEM. ** p,0.01. Scale bar 200 mm for A. Scale bar 50 mm for B
doi:10.1371/journal.pone.0075189.g003
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or an indirect consequence caused by an alteration in neuronal
environment. Here, we demonstrated that diazoxide preserves
motoneuron viability against excitotoxic, oxidative and inflamma-
tory neurodegenerative insults. When we study neuroprotection in
a more complex system where intercellular relationships and the
histoarchitecture are preserved, like the organotypic hippocampal
cultures, we found that diazoxide treatment preserve NMDA-
induced cell death even at low concentrations. Moreover, when we
depleted microglia from these cultures we observed that the effect
was sustained at the lowest dose, suggesting a direct neuroprotec-
tive effect independent of microglial cells. These results also
suggest that diazoxide could have different mechanisms of action
that causes neuroprotection depending of the concentration of
drug. Although further experiments would be needed to better
understand which exact cellular pathways are involved, low doses
of diazoxide have been reported to be selective for the activation of
mito-KATP channels [48,49]. Garlid and coll. compared reconsti-
tuted cardiac mito-KATP with reconstituted cardiac sarcolemmal
KATP (sarc-KATP) channels and showed that mito-KATP channel is
about 2000 times more sensitive to diazoxide than sarc-KATP
channels, indicating that two distinct receptor subtypes coexist
within the myocytes [50]. Other authors found that interaction
between mito-KATP channel and protein kinase C epsilon (ePKC)
during ischemic preconditioning (IPC) induction preserves the
hippocampal CA1 region after ischemia. Interestingly, these
results showed that only low concentrations of diazoxide were
neuroprotective [51]. Several studies confirmed that the protection
towards neurons conferred by diazoxide is mainly mediated by
mito-KATP [52–54], but, unfortunately, the exact mechanism and
structure of mito-KATP itself is still controversial [55,56]. In this
way, our results suggest that diazoxide has a direct effect on
neurons and, as this is produced at low doses, this effect could be
through activation of mito-KATP channels.
It has been shown that mito-KATP activation by diazoxide
prevents neuronal oxidative stress and excitotoxic cell death in
part by reducing intracellular ROS level [46]. Moreover, it is
reported that diazoxide, acting at mitochondrial level, can activate
defensive and anti-apoptotic mechanisms [8]. Among other
pathways, Nrf2 transcription factor has been postulated as one
of the main components of cell self-defense against oxidative
damage and mitochondrial dysfunction [57–60]. To maintain a
physiological redox balance, cells are equipped with a wide variety
of endogenous antioxidant enzymes. Production of these cytopro-
tective enzymes is induced upon exposure to ROS via a
mechanism regulated at the transcriptional level [61]. Genes that
code for proteins involved in ROS detoxification share a common
promoter element, called the antioxidant response element (ARE).
ARE-mediated gene activation is coordinated by Nrf2, which,
upon exposure to electrophiles or ROS, translocates to the nucleus
and activates antioxidant enzyme gene transcription [62,63].
Here, we demonstrated that low doses of diazoxide increase Nrf2
nuclear translocation in neurons. After neuron exposure to
endogenous oxidative stress promoted by AAPH, diazoxide
treatment exerts neuroprotection, but only at low doses, in
concordance with the concentrations observed to promote Nrf2
activation. These results suggest that diazoxide neuroprotection
could be partially due to the activation of endogenous antioxidant
pathways mediated at mitochondrial level. Moreover, when Nrf2
activation was studied in diazoxide EAE treated animals, an
increase of this nuclear factor was observed in spinal cord. In EAE
animals, protective effects of different exogenous antioxidants have
been described [64,65]. However, another alternative strategy to
inhibit the detrimental effects of ROS is through the induction of
endogenous antioxidants enzymes [66]. In this way, as we just
mentioned, the translocation of Nrf2 to the nucleus in neurons of
EAE animals treated with diazoxide could be the cause of Nrf2
endogenous anti-oxidant pathway activation, and this might
produce a neuroprotective effect. Interestingly, in this way, Nrf2
activation has been described as the key mechanism of action for
BG-12, a novel therapeutic compound for the treatment of MS
[32,33,67]. Finally, when we study whether diazoxide could have a
protective effect in LPS induced demyelination, we observed that
the treatment can also prevent myelin loss in cerebellar cultures.
Since diazoxide has been reported to promote oligodendrocyte
Figure 4. Diazoxide increases Nrf2 nuclear translocation in NSC-34 motoneurons and prevents endogenous oxidative damage.
Western blot showed an increase of Nrf2 signaling in the nuclear extracts from NSC-34 neurons treated with different doses of diazoxide for 24 h. The
higher increase of Nrf2 was found at lower doses (10 and 1 mM) (A). Cell viability of NSC-34 cells was measured after 24 h AAPH oxidative stress
activation and results demonstrated that diazoxide treatment effectively ameliorates cell viability at low doses (B). Results expressed as mean 6 SEM.
n$4 experiments. *: p , 0.05, ** p,0.01. Scale bar = 30 mm
doi:10.1371/journal.pone.0075189.g004
Antioxidative Effect of Diazoxide Protects Neurons
PLOS ONE | www.plosone.org 8 September 2013 | Volume 8 | Issue 9 | e75189
precursor cell proliferation and myelination [68] and inhibit
inflammatory glial reactivity [30], more studies would be needed
to clarify the possible role of diazoxide in myelin repair. Taken
together these results suggest that diazoxide is a promising
neuroprotective agent for the protection of oxidative stress-
induced damage and dysfunction in neurodegenerative and
inflammatory diseases such MS.
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